The therapy is designed to work even if different patients express different cancer "flags." More critically, it targets multiple flags within a single patient's heterogeneous tumor. This reduces the risk of cancer cells that lack a single target surviving and causing treatment resistance, aiming for deeper and more durable responses.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

Over 99% of cancer-specific targets are proteins located inside the cell, making them invisible to traditional antibody therapies. DEC-Bio's platform leverages the peptide MHC system, which naturally presents fragments of these internal proteins on the cell surface. This effectively unlocks a vast new library of highly cancer-specific targets.

While engineering to recognize four distinct targets is complex, DEC-Bio intentionally designs its final therapy to have a simple, bispecific antibody format. This focus on "developability" — ease of manufacturing and formulation — is a core strategic choice to avoid the pitfalls of overly complex "Frankenstein" molecules and ensure a commercially viable product.

While some firms repurpose cancer T-cell engagers (TCEs), a new wave of innovation is emerging from China. These biotechs are designing novel, "fit-for-purpose" constructs like trispecifics and molecules with co-stimulatory receptors specifically for the unique safety and efficacy demands of autoimmune disease.

The company not only identifies targets from its elite patient cohort but also isolates the corresponding T-cell receptors (TCRs). Because these TCRs have been circulating safely in patients for years, they offer a strong starting point for safety. They are also naturally "highly selected," providing significant initial affinity for their targets, which can accelerate development.

Instead of complex ex-vivo cell engineering, Zag Bio's antibody platform programs the body's own thymus to produce long-lived, antigen-specific regulatory T-cells. This approach simplifies the therapeutic process by turning the organ into a drug-producing factory.

Mini-proteins are framed as a superior drug modality that merges the key strengths of traditional therapies. They possess the high selectivity characteristic of biologics like antibodies, while also having the stability and formulation advantages of small-molecule drugs. This combination allows them to precisely target difficult receptors while avoiding common off-target effects or instability issues.

Unlike permanent gene-editing, the company's mRNA-based CAR-T therapy is transient, with T-cell programming lasting only 7-10 days. This temporary effect enhances safety by avoiding permanent genetic changes and provides crucial flexibility to repeat or adjust dosing to achieve desired durability, much like a traditional drug.